Allergy & Immunologyautoimmune hepatitissteroid-sparing therapy
Zetomipzomib Shows Promise in Difficult-to-Treat Autoimmune Hepatitis: Insights from the Phase 2a PORTOLA Study
By MedXY|Sep 25, 2026
The PORTOLA phase 2a trial evaluates zetomipzomib, a selective immunoproteasome inhibitor, demonstrating numerically improved biochemical remission and steroid-sparing effects in autoimmune hepatitis patients with inadequate response to sta